Hikma Pharmaceuticals PLC.
History
| Year | Detail |
|---|---|
| 1978 | Hikma Pharmaceuticals PLC was founded by Samih Darwazah in Amman, Jordan, to provide high-quality and affordable medicines to needy patients. |
| 2007 | Hikma Pharmaceuticals acquired Alkan Pharma, an Egyptian pharmaceutical company, for $60.5 million in cash. This acquisition helped Hikma enter the Egyptian market and strengthened its presence in Jordan by acquiring Arab Pharmaceutical Manufacturing Company (APM) worth $163.6 million. |
| 2011 | The company acquired Baxter Healthcare Corporation’s U.S. generic injectables business (Multi-Source Injectables) for $112 million, significantly enhancing the scale and scope of its global Injectables platform. |
| 2022 | Hikma Pharmaceuticals acquired the Canadian assets of Teligent Inc. for $45.75 million, which marks Hikma’s expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products, and a pipeline of seven additional products, four of which are approved by Health Canada. |
| 2022 | The company acquired Custopharm Inc. from Water Street Healthcare Partners following approval from the U.S. Federal Trade Commission. The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline, expanding its differentiated U.S. portfolio to nearly 130 commercialized injectable medicines. |
BCC Research Beacon 